Key result
Tirzepatide use linked to unprovoked upper extremity deep vein thrombosis in a new case report.
Case Report (n=1)
This case report highlights a potential, albeit rare, association between tirzepatide use and the development of acute deep vein thrombosis in patients with predisposing risk factors such as obesity.
May warrant vigilance for unprovoked DVT in tirzepatide users; leaves open whether this represents a causal signal requiring dedicated pharmacovigilance.
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 agonist, is gaining popularity for its weight reduction, improved glycemic control, and cardiorenal benefits. While it is generally well tolerated, thrombotic events have not been commonly reported. We report a case of a woman who developed an unprovoked deep vein thrombosis within months of starting tirzepatide. An extensive hypercoagulability workup was negative. Her symptoms improved with anticoagulation and discontinuation of tirzepatide. This case highlights a potential risk of thromboembolic events associated with tirzepatide. Clinicians need to be vigilant and exercise extreme caution as the emerging adverse event profile of this novel medication unfolds.
No takes yet. Share an insight, caveat, or question.
Sonavane et al. (2025) conducted a case report in Deep Vein Thrombosis (n=1). Tirzepatide was evaluated on Deep Vein Thrombosis. A 57-year-old woman developed an unprovoked left upper extremity deep vein thrombosis after 8 months of tirzepatide use, highlighting a possible association requiring further pharmacovigilance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: